Cargando…
Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072898/ https://www.ncbi.nlm.nih.gov/pubmed/33912040 http://dx.doi.org/10.3389/fphar.2021.618846 |
_version_ | 1783684011218960384 |
---|---|
author | Wu, Jianxiong Ye, Xietao Yang, Songhong Yu, Huan Zhong, Lingyun Gong, Qianfeng |
author_facet | Wu, Jianxiong Ye, Xietao Yang, Songhong Yu, Huan Zhong, Lingyun Gong, Qianfeng |
author_sort | Wu, Jianxiong |
collection | PubMed |
description | Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells that then affect the liver’s normal function, causing a series of symptoms and abnormal liver function indicators. Citri Reticulatae Pericarpium (CRP) is one of the most commonly used traditional Chinese medicines; it contains flavonoids including hesperidin, nobiletin, and tangeretin. CRP has antibacterial, antioxidant, and antitumor effects that reduce cholesterol, prevent atherosclerosis and decrease LI. Here we analyzed the components of CRP and their targets of action in LI treatment and assessed the relationships between them using a systems pharmacology approach. Twenty-five active ingredients against LI were selected based on ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry results and databases. The drug targets and disease-related targets were predicted. The 117 common targets were used to construct a protein-protein interaction network. We identified 1719 gene ontology items in LI treatment, including 1,525 biological processes, 55 cellular components, and 139 molecular functions. These correlated with 49 Kyoto Encyclopedia of Genes and Genomes pathways. These findings suggest that CRP may counteract LI by affecting apoptotic, inflammatory, and energy metabolism modules. In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI. This study provides a reference for systematically exploring the mechanism of CRP’s anti-LI action and is also expands of the application of systems pharmacology in the study of traditional Chinese medicine. |
format | Online Article Text |
id | pubmed-8072898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80728982021-04-27 Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium Wu, Jianxiong Ye, Xietao Yang, Songhong Yu, Huan Zhong, Lingyun Gong, Qianfeng Front Pharmacol Pharmacology Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells that then affect the liver’s normal function, causing a series of symptoms and abnormal liver function indicators. Citri Reticulatae Pericarpium (CRP) is one of the most commonly used traditional Chinese medicines; it contains flavonoids including hesperidin, nobiletin, and tangeretin. CRP has antibacterial, antioxidant, and antitumor effects that reduce cholesterol, prevent atherosclerosis and decrease LI. Here we analyzed the components of CRP and their targets of action in LI treatment and assessed the relationships between them using a systems pharmacology approach. Twenty-five active ingredients against LI were selected based on ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry results and databases. The drug targets and disease-related targets were predicted. The 117 common targets were used to construct a protein-protein interaction network. We identified 1719 gene ontology items in LI treatment, including 1,525 biological processes, 55 cellular components, and 139 molecular functions. These correlated with 49 Kyoto Encyclopedia of Genes and Genomes pathways. These findings suggest that CRP may counteract LI by affecting apoptotic, inflammatory, and energy metabolism modules. In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI. This study provides a reference for systematically exploring the mechanism of CRP’s anti-LI action and is also expands of the application of systems pharmacology in the study of traditional Chinese medicine. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072898/ /pubmed/33912040 http://dx.doi.org/10.3389/fphar.2021.618846 Text en Copyright © 2021 Wu, Ye, Yang, Yu, Zhong and Gong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Jianxiong Ye, Xietao Yang, Songhong Yu, Huan Zhong, Lingyun Gong, Qianfeng Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title | Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title_full | Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title_fullStr | Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title_full_unstemmed | Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title_short | Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium |
title_sort | systems pharmacology study of the anti-liver injury mechanism of citri reticulatae pericarpium |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072898/ https://www.ncbi.nlm.nih.gov/pubmed/33912040 http://dx.doi.org/10.3389/fphar.2021.618846 |
work_keys_str_mv | AT wujianxiong systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium AT yexietao systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium AT yangsonghong systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium AT yuhuan systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium AT zhonglingyun systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium AT gongqianfeng systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium |